Medicus 2014;23(1):69-70
kušaj njegove daljnje primjene u liječenju sepse u kombinaciji
s ostalim antibioticima. Poboljšan učinak više se očekuje od
njegova protuupalnog djelovanja negoli od same antibakterij-
ske aktivnosti (23).
LITERATURA
1.
Kutlesa M, Lepur D, Daković-Rode O, Schoenwald N, Barsić B. Severe
late-onset nosocomial pneumonia causedbyChlamydophilapneumo-
niae.ActaClinCroat2009;48:179–82.
2.
Torres A, Serra-Batlles J, Ferrer A i sur. Severe community-acquired
pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis
1991;144:312–8.
3.
Leroy O, Saux P, Bédos JP, Caulin E. Comparison of levofloxacin and
cefotaxime combined with ofloxacin for ICU patients with commu-
nity-acquired pneumonia who do not require vasopressors. Chest
2005;128:172–83.
4.
Mandell LA, Wunderink RG, Anzueto A i sur. Infectious Diseases
Society of America; AmericanThoracic Society. Infectious Diseases
Society of America/American Thoracic Society consensus guide-
lines on the management of community-acquired pneumonia in
adults. Clin Infect Dis 2007;44(Suppl 2):S27–72.
5.
Berger A1, Edelsberg J, Oster G, Huang X, Weber DJ. Patterns of initial
antibiotic therapy for community-acquired pneumonia in u.s. Hospi-
tals,2000to2009.AmJMedSci2014;347(5):347-56.
6.
Kuzman I, Daković-Rode O, Oremus M, Banaszak AM. Clinical effi-
cacy and safety of a short regimen of azithromycin sequential the-
rapy vs standard cefuroxime sequential therapy in the treatment of
community-acquired pneumonia: an international, randomized,
open-label study. J Chemother 2005;17:636–42.
7.
Vergis EN, Indorf A, File TM Jr. i sur. Azithromycin vs cefuroxime plus
erythromycin for empirical treatment of community-acquired pneu-
monia inhospitalizedpatients: aprospective,randomized,multicenter
trial.ArchInternMed2000;160:1294–300.
8.
Plouffe J, Schwartz DB, Kolokathis A i sur. Clinical efficacy of intravenous
followed by oral azithromycinmonotherapy in hospitalized patients with
community-acquiredpneumonia.TheAzithromycinIntravenousClinical
TrialsGroup.AntimicrobAgentsChemother2000;44:1796–802.
9.
FeldmanRB,RhewDC,WongJY,CharlesRA,GoetzMB;AmericanTho-
racicSociety.Azithromycinmonotherapyforpatientshospitalizedwith
community-acquired pneumonia: a 31/2-year experience from a vete-
ransaffairshospital.ArchInternMed2003;163:1718–26.
10. Baddour LM, Yu VL, Klugman KP i sur. International Pneumococcal
Study Group. Combination antibiotic therapy lowers mortality among
severely ill patients with pneumococcal bacteremia. Am J Respir Crit
CareMed2004;170:440–4.
11. Kumar A, Zarychanski R, Light B i sur. Cooperative Antimicrobial The-
rapyofSepticShock(CATSS)DatabaseResearchGroup.Earlycombina-
tion antibiotic therapy yields improved survival comparedwithmono-
therapy in septic shock: a propensity-matched analysis. Crit Care Med
2010;38(9):1773–85.
12. Martin-Loeches I, Lisboa T, Rodriguez A i sur. Combination antibiotic
therapy with macrolides improves survival in intubated patients with
community-acquiredpneumonia.IntensiveCareMed2010;36:612–20.
13. Inai K, IwasakiH, NaikiH, UedaT. Azithromycin reduces tumor necro-
sis factor-alpha production in lipopolysaccharide-stimulated THP-1
monocytic cells bymodification of stress response and p38MAPK pat-
hway.JChemother2009;21:396–402.
14. BosnarM,BosnjakB,CuzicSisur.Azithromycinandclarithromycinin-
hibit lipopolysaccharide-inducedmurine pulmonary neutrophiliama-
inly through effects on macrophage-derived granulocyte-macrophage
colony-stimulating factor and interleukin-1beta. J Pharmacol ExpTher
2009;331:104–13.
15. MarjanovićN,BosnarM,MichielinFisur.Macrolideantibioticsbroadly
and distinctively inhibit cytokine and chemokine production by COPD
sputumcellsinvitro.PharmacolRes2011;63(5):389-97.
16. JangMO, JangHC, KimUJ i sur. Outcome of intravenous azithromycin
therapy inpatientswith complicated scrub typhus comparedwith that
of doxycycline therapyusingpropensity-matchedanalysis. Antimicrob
AgentsChemother2014;58:1488–93.
17. Phimda K, Hoontrakul S, Suttinont C i sur. Doxycycline versus azit-
hromycin for treatment of leptospirosis and scrub typhus. Antimicrob
AgentsChemother2007;51:3259–63.
18. SavarisRF,TeixeiraLM,TorresTG,EdelweissMI,MoncadaJ,Schachter
J. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic
inflammatory disease: a randomized controlled trial. Obstet Gynecol.
2007;110:53–60.
19. GottliebJ,SzangoliesJ,KoehnleinT,GolponH,SimonA,WelteT.Long-
term azithromycin for bronchiolitis obliterans syndrome after lung
transplantation.Transplantation2008;85:36–41.
20. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of
azithromycinvs.doxycyclineinthetreatmentofrosacea:arandomized
openclinicaltrial.IntJDermatol2008;47:284–8.
21. Saxena VN, Dogra J. Long-term oral azithromycin in chronic plaque
psoriasis:acontrolledtrial.EurJDermatol2010;20:329–33.
22. Valery PC, Morris PS, Byrnes CA i sur. Long-term azithromycin for In-
digenous children with non-cystic-fibrosis bronchiectasis or chronic
suppurative lung disease (Bronchiectasis Intervention Study): a multi-
centre, double-blind, randomised controlled trial. Lancet Respir Med
2013;1:610–20.
23. Mal P, Dutta K, Bandyopadhyay D, Basu A, Khan R, Bishayi B. Azi-
thromycin in combination with riboflavin decreases the severity of
Staphylococcusaureusinfectioninducedsepticarthritisbymodulating
theproductionoffreeradicalsandendogenouscytokines.InflammRes
2013;62:259–73.
70
Barišić B.
Prof. dr. sc. Bruno Baršić, dr. med.
Klinika za infektivne bolesti “Dr. Fran Mihaljević”
10000 Zagreb, Mirogojska 8
